22-25G for intramuscular), carries lower infection risk, and is technically simpler
If youre accepted, youll receive a test kit for submitting a blood sample to Amazentis SA, and your anonymized results will be part of an open-label clinical study (youll get your own personal results sent to you, too)
Basic mechanisms of generalized absence seizures
The key regulatory milestones: FDA Breakthrough Therapy designation for MASH (September 2024) EMA PRIME designation for MASH (November 2023) China NMPA Breakthrough designation (June 2024) Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) fully enrolled, results expected H1 of this year Estimated FDA filing: Late this year at the earliest Estimated FDA approval: Possibly next year, depending on Phase 3 results If Phase 3 results confirm Phase 2 findings, survodutide could reach the market within the next 12-24 months
Routes of Administration Dihexa can theoretically be administered through multiple routes, each with different pharmacokinetic properties: Oral (Sublingual and Swallowed) Sublingual administration: Some users hold tablets under the tongue to attempt direct oral mucosal absorption, hypothetically bypassing digestive breakdown
Container type
